Ultromics Secures £41,400,000 for Cardiovascular Innovation
Revolutionizing Cardiology: Ultromics Secures £41,400,000 in Funding
In an exciting move for the healthcare sector, Ultromics, a pioneering AI-driven cardiology firm based in Oxford, UK, has successfully raised £41,400,000 (GBP) in Series C funding. This substantial investment round was spearheaded by industry titans such as L&G, Allegis Capital, and Lightrock, alongside robust backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Notably, UChicago Medicine’s venture investment vehicle, UCM Ventures, and UPMC Enterprises also threw their weight behind this transformative company. With these new capital influxes, Ultromics is set to accelerate its operations and enhance vital research and development efforts in the realm of cardiovascular care.
Ultromics is at the forefront of revolutionizing heart disease diagnostics through its innovative EchoGo® platform, which integrates artificial intelligence with echocardiography.
This groundbreaking tool, developed in collaboration with the NHS and Mayo Clinic, empowers clinicians by facilitating the early and precise detection of complex heart diseases using routine ultrasound scans. To date, Ultromics has analyzed over 430,000 echocardiograms, with remarkable clinical outcomes. In fact, studies show that EchoGo improves the detection of heart failure with preserved ejection fraction (HFpEF) by an impressive 73.6% compared to conventional clinical risk scores, providing a potent offering for both healthcare providers and patients alike.
Ultromics’ continued commitment to innovation is evidenced by its latest diagnostic model for cardiac amyloidosis. This model has undergone rigorous validation in a global study comprising 18 prominent institutions and has been featured in the European Heart Journal. The findings reveal its ability to outshine existing clinical risk scores, significantly enhancing disease differentiation from similar conditions. For startup founders and investors in the healthcare space, Ultromics represents a compelling investment opportunity, as it not only demonstrates extensive funding support but also a steadfast trajectory towards redefining cardiovascular healthcare through intelligent technology.
Key Terms Explained
- Series C funding
- This is the third round of funding for companies that have proved their business concept, shown steady revenue streams and are seeking funds to scale and grow rapidly.
- Artificial Intelligence (AI) in Healthcare
- This refers to the use of complex algorithms and software to emulate human cognition in the analysis, interpretation, and comprehension of complicated medical and healthcare data.
- Echocardiography
- A diagnostic test that uses ultrasound waves to produce images of the heart. It allows doctors to observe the functioning of the heart and identify any abnormalities.
Frequently Asked Questions
- How much funding was raised by Ultromics in its Series C round?-In its Series C funding round, Ultromics successfully raised £41,400,000.
- Who are some of the major investors in Ultromics?+
- What is the primary focus of Ultromics' technology?+
- What was the impact of Ultromics' funding on its operations?+
- What makes Ultromics a compelling investment opportunity?+
They've invested in Ultromics
Get to know these AI investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 L&G | 1 investment investment | more info | |||
 Allegis Capital | 1 investment investment | more info | |||
 Lightrock | 2 investments investments | 1 contact contact | |||
 Oxford Science Enterprises | 28 investments investments | 1 contact contact | |||
 Google Ventures | 15 investments investments | 14 contacts contacts | |||
 Blue Venture Fund | 1 investment investment | more info | |||
 University of Oxford | 9 investments investments | more info | |||
 UCM Ventures | 2 investments investments | more info | |||
 UPMC Enterprises | 2 investments investments | more info |
Click here for a full list of 7,526+ startup investors in the UK